Abiomed losses narrow for FY2009, Q4; bolstered by strong Impella sales

Abiomed, a provider of heart support technologies, has reported fourth quarter of fiscal 2009 revenue of $19.6 million, which is up 12 percent compared to revenue of $17.5 million for the 2008 fourth fiscal quarter.

Total revenue for the 12 months ended March 31 was $73.2 million, up 24 percent compared to revenue of $58.9 million for the full year fiscal 2008. Full-year fiscal 2009 worldwide Impella revenue was $36.4 million, up 196 percent compared to Impella revenue of $12.3 million for fiscal 2008, due to its FDA approval.

The Danvers, Mass.-based company said its generally accepted accounting principles (GAAP) net loss was $8.5 million for this quarter, compared to a GAAP net loss of $15 million during the fourth quarter of fiscal 2008. The full year fiscal 2009 GAAP net loss was $31.6 million, compared to a GAAP net loss of $40.9 million for the full year fiscal 2008.

For its 2009 fiscal fourth quarter, the company said its worldwide Impella revenue was $11.2 million, up 124 percent compared to revenue of $5 million for the year-ago quarter.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."